Literature DB >> 20081870

Disease-associated functions of IL-33: the new kid in the IL-1 family.

Foo Y Liew1, Nick I Pitman, Iain B McInnes.   

Abstract

Interleukin-33 (IL-33), a newly described member of the IL-1 family, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The IL-33 receptor, consisting of ST2 and IL-1 receptor accessory protein, is also widely expressed, particularly by T helper 2 (T(H)2) cells and mast cells. IL-33 is host-protective against helminth infection and reduces atherosclerosis by promoting T(H)2-type immune responses. However, IL-33 can also promote the pathogenesis of asthma by expanding T(H)2 cells and mediate joint inflammation, atopic dermatitis and anaphylaxis by mast cell activation. Thus IL-33 could be a new target for therapeutic intervention across a range of diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20081870     DOI: 10.1038/nri2692

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  69 in total

Review 1.  Alarmins: chemotactic activators of immune responses.

Authors:  Joost J Oppenheim; De Yang
Journal:  Curr Opin Immunol       Date:  2005-08       Impact factor: 7.486

2.  Elevation of ST2 protein levels in cerebrospinal fluid following subarachnoid hemorrhage.

Authors:  M Kanda; H Ohto-Ozaki; K Kuroiwa; S Tominaga; E Watanabe; H Iwahana
Journal:  Acta Neurol Scand       Date:  2006-05       Impact factor: 3.209

3.  IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells.

Authors:  Shafaqat Ali; Michael Huber; Christian Kollewe; Stephan C Bischoff; Werner Falk; Michael U Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-14       Impact factor: 11.205

Review 4.  IL-1, IL-18, and IL-33 families of cytokines.

Authors:  William P Arend; Gaby Palmer; Cem Gabay
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

5.  An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor.

Authors:  Maho Suzukawa; Motoyasu Iikura; Rikiya Koketsu; Hiroyuki Nagase; Chise Tamura; Akiko Komiya; Susumu Nakae; Kouji Matsushima; Ken Ohta; Kazuhiko Yamamoto; Masao Yamaguchi
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

6.  Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1.

Authors:  K Yanagisawa; T Takagi; T Tsukamoto; T Tetsuka; S Tominaga
Journal:  FEBS Lett       Date:  1993-02-22       Impact factor: 4.124

7.  Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

Authors:  Gaby Palmer; Dominique Talabot-Ayer; Céline Lamacchia; Dean Toy; Christian A Seemayer; Sébastien Viatte; Axel Finckh; Dirk E Smith; Cem Gabay
Journal:  Arthritis Rheum       Date:  2009-03

8.  Interleukin-33 is biologically active independently of caspase-1 cleavage.

Authors:  Dominique Talabot-Ayer; Céline Lamacchia; Cem Gabay; Gaby Palmer
Journal:  J Biol Chem       Date:  2009-05-22       Impact factor: 5.157

9.  IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex.

Authors:  Quentin Espinassous; Elvira Garcia-de-Paco; Ignacio Garcia-Verdugo; Monique Synguelakis; Sonja von Aulock; Jean-Michel Sallenave; Andrew N J McKenzie; Jean Kanellopoulos
Journal:  J Immunol       Date:  2009-06-24       Impact factor: 5.422

10.  Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology.

Authors:  G Walzl; S Matthews; S Kendall; J C Gutierrez-Ramos; A J Coyle; P J Openshaw; T Hussell
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

View more
  372 in total

Review 1.  Deciphering the structure and function of FcεRI/mast cell axis in the regulation of allergy and anaphylaxis: a functional genomics paradigm.

Authors:  Jayapal Manikandan; Narasimhan Kothandaraman; Manoor Prakash Hande; Peter Natesan Pushparaj
Journal:  Cell Mol Life Sci       Date:  2011-12-07       Impact factor: 9.261

2.  Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B.

Authors:  Juan Wang; Yanjun Cai; Huifan Ji; Junyan Feng; Desalegn Admassu Ayana; Junqi Niu; Yanfang Jiang
Journal:  J Interferon Cytokine Res       Date:  2012-02-03       Impact factor: 2.607

3.  Regulation of innate CD8+ T-cell activation mediated by cytokines.

Authors:  Bailey E Freeman; Erika Hammarlund; Hans-Peter Raué; Mark K Slifka
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

Review 4.  Early detection of myocardial dysfunction and heart failure.

Authors:  Geoffrey de Couto; Maral Ouzounian; Peter P Liu
Journal:  Nat Rev Cardiol       Date:  2010-05-11       Impact factor: 32.419

5.  Interleukin-33 safeguards neutrophils in sepsis.

Authors:  Thierry Roger; Thierry Calandra
Journal:  Nat Med       Date:  2010-06       Impact factor: 53.440

Review 6.  IL-33 family members and asthma - bridging innate and adaptive immune responses.

Authors:  Clare M Lloyd
Journal:  Curr Opin Immunol       Date:  2010-11-09       Impact factor: 7.486

7.  Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells.

Authors:  Kuan-Min Fang; Chung-Shi Yang; Tzu-Chien Lin; Ti-Chun Chan; Shun-Fen Tzeng
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

8.  Interleukin-33 in the human placenta.

Authors:  Vanessa Topping; Roberto Romero; Nandor Gabor Than; Adi L Tarca; Zhonghui Xu; Sun Young Kim; Bing Wang; Lami Yeo; Chong Jai Kim; Sonia S Hassan; Jung-Sun Kim
Journal:  J Matern Fetal Neonatal Med       Date:  2012-11-23

9.  Serum amyloid A induces interleukin-33 expression through an IRF7-dependent pathway.

Authors:  Lei Sun; Ziyan Zhu; Ni Cheng; Qian Yan; Richard D Ye
Journal:  Eur J Immunol       Date:  2014-05-22       Impact factor: 5.532

10.  IL-33 markedly activates murine eosinophils by an NF-κB-dependent mechanism differentially dependent upon an IL-4-driven autoinflammatory loop.

Authors:  Carine Bouffi; Mark Rochman; Christopher B Zust; Emily M Stucke; Andrey Kartashov; Patricia C Fulkerson; Artem Barski; Marc E Rothenberg
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.